Genmab A/S (NASDAQ:GMAB) Now Covered by Truist Financial

Investment analysts at Truist Financial initiated coverage on shares of Genmab A/S (NASDAQ:GMAB) in a research report issued to clients and investors on Wednesday, Marketbeat Ratings reports. The firm set a “buy” rating and a $40.00 price target on the stock. Truist Financial’s price objective would indicate a potential upside of 48.75% from the stock’s current price.

GMAB has been the topic of several other reports. BNP Paribas Exane upgraded Genmab A/S from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, April 22nd. Wells Fargo & Company assumed coverage on Genmab A/S in a research note on Monday, March 2nd. They set an “overweight” rating and a $40.00 target price on the stock. Wall Street Zen cut Genmab A/S from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. Morgan Stanley began coverage on Genmab A/S in a research note on Monday, February 16th. They issued an “equal weight” rating and a $34.00 price target for the company. Finally, Wolfe Research began coverage on shares of Genmab A/S in a research report on Friday, March 27th. They set an “outperform” rating and a $32.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Genmab A/S currently has a consensus rating of “Moderate Buy” and a consensus price target of $37.93.

Genmab A/S Stock Up 0.1%

GMAB opened at $26.89 on Wednesday. The stock has a market cap of $16.77 billion, a price-to-earnings ratio of 20.37, a price-to-earnings-growth ratio of 1.60 and a beta of 0.86. The company has a debt-to-equity ratio of 0.87, a quick ratio of 2.17 and a current ratio of 2.18. The firm’s fifty day moving average is $26.99 and its 200 day moving average is $29.67. Genmab A/S has a fifty-two week low of $20.23 and a fifty-two week high of $35.43.

Hedge Funds Weigh In On Genmab A/S

Institutional investors have recently added to or reduced their stakes in the company. Personal CFO Solutions LLC raised its holdings in shares of Genmab A/S by 3.7% during the 1st quarter. Personal CFO Solutions LLC now owns 10,866 shares of the company’s stock worth $292,000 after acquiring an additional 386 shares in the last quarter. Founders Capital Management grew its holdings in shares of Genmab A/S by 40.0% in the fourth quarter. Founders Capital Management now owns 1,400 shares of the company’s stock valued at $43,000 after purchasing an additional 400 shares in the last quarter. Parallel Advisors LLC increased its position in Genmab A/S by 11.3% in the third quarter. Parallel Advisors LLC now owns 4,139 shares of the company’s stock worth $127,000 after purchasing an additional 419 shares during the last quarter. CWM LLC increased its position in Genmab A/S by 18.8% in the fourth quarter. CWM LLC now owns 2,739 shares of the company’s stock worth $84,000 after purchasing an additional 433 shares during the last quarter. Finally, Jones Financial Companies Lllp raised its stake in Genmab A/S by 29.1% during the third quarter. Jones Financial Companies Lllp now owns 1,951 shares of the company’s stock valued at $57,000 after purchasing an additional 440 shares in the last quarter. Hedge funds and other institutional investors own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.